Navigation Links
Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
Date:8/6/2009

HOUSTON, Aug. 6 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

BP-GMAX-CD1 is a novel cancer vaccine that can be precisely activated at an optimal time and location in the body. It is produced by genetically modifying autologous antigen-loaded dendritic cells to express an inducible costimulatory CD40 (iCD40) receptor. Twenty-four hours after intradermal administration, these genetically modified dendritic cells are activated in draining lymph nodes by intravenous administration of AP1903, a small-molecule dimerizer agent developed by ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA). In this way, the immune system's innate homeostasis is overridden and a potent and durable antigen-specific T cell response may be generated.

The dose-escalation trial will evaluate the safety of BP-GMAX-CD1 and AP1903 in a minimum of 24 patients with androgen independent prostate cancer (also known as castrate resistant prostate cancer or CRPC). Six doses will be administered on a weekly or every other week schedule, with responses assessed at week 13. Patients whose disease has not progressed at the end of this acute phase will be eligible to receive booster vaccinations every eight weeks for up to one year. Exploratory efficacy endpoints include prostate-specific antigen dynamics, circulating tumor cell count, antigen-specific immune response, and clinical response. Additional information can be found at www.clinicaltrials.gov.

Bellicum Founder, President and Chief Medical Officer, Kevin M. Slawin, M.D., stated, "This first clinical trial of BP-GMAX-CD1 is designed to establish proof of principle for our core iCD40 technology, which has been engineered to overcome the critical potency limitations of previous cancer vaccine strategies. Dosing the first patient is an exciting and significant milestone in our quest to deliver safer and more effective therapies to patients with advanced cancer."

The small-molecule dimerizer, AP1903, and the ARGENT(TM) cell-signaling regulation technology underlying BP-GMAX-CD1 were licensed from ARIAD Pharmaceuticals, Inc. AP1903 is designed to bring together two proteins and activate them. In the case of BP-GMAX-CD1, administration of AP1903 to patients leads to controlled activation of the ARGENT-regulated protein iCD40. AP1903 was previously shown by ARIAD to be well-tolerated with defined pharmacokinetics in a Phase 1 clinical trial.

"This is an exciting application of ARIAD's dimerizer technology, with the potential for therapeutic benefit linked to precise control of signaling events inside cells," stated Timothy P. Clackson, Ph.D., Senior Vice President and Chief Scientific Officer of ARIAD. "We congratulate Bellicum on this first application of the dimerizer technology in cancer patients."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. The company's lead product, BP-GMAX-CD1, a genetically modified, pharmacologically regulated autologous vaccine, is in clinical development for patients with advanced, androgen independent prostate cancer. BP-GMAX-CD1 and follow-on product candidates have been successfully tested in mouse models and human dendritic cells. The company owns or has in-licensed certain key technologies, and Chief Executive Officer Thomas J. Farrell has assembled a team of seasoned clinical, regulatory, quality and CMC consultants to advance product candidates into human clinical trials. For more information, visithttp://www.bellicum.com


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bellicum Pharmaceuticals Announces $3.75 Million in Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: